-transparent.png){kind=logo}
The structure and the expression of 11 cellular oncogenes (protooncogenes) were analyzed in primary cells from 20 acute lymphocytic (ALL) and 31 acute myelogenous (AML) leukemia patients. Neoplastic cells, obtained prior to initiation of therapy, were purified and classified, on the basis of both surface antigen pattern and morphology, into pre-B, B, and T ALL and M1-M5 AML. RNA was extracted and analyzed for expression of cellular oncogenes coding for nuclear proteins (c-myc, c-myb, c-fos), the beta-chain of platelet-derived growth factor (c-sis), growth factor receptors or related proteins (c-src, c-abl, c-fes, c-erbB), or putative intermediate transducers of mitogenic signals (c-Ha-ras, c-Ki-ras, c-N-ras). Quantitative analysis of total RNA was carried out by dot blot hybridization to specific cDNA or genomic probes. Number and size of transcripts were evaluated by blot hybridization of electrophoretically fractionated poly(A)+ RNA. Expression of c-myc and c-myb was detected in all leukemic cells at variable levels and was characterized by well-defined patterns within ALL subtypes. Conversely, significant levels of c-fos transcripts were detected only in myelomonocytic (M4) and monocytic (M5) leukemias. Among the "src-family," c-fes was expressed more in AML than ALL, and c-abl was expressed at variable but not elevated levels in all leukemia types. c-Ha-ras was uniformly expressed at low levels, as in non-neoplastic cells. c-Ki-ras transcription was detected only in T ALL; N-ras expression was barely demonstrable. The structure of these protooncogenes was not grossly modified, as evaluated by Southern analysis, except for c-myc rearrangement in B ALL. These studies indicate that cellular oncogene expression in specific subtypes of leukemic cells may relate to either the proliferative activity (c-myc, c-myb) or the differentiation state (c-fos) of the cells, or possibly to expression of receptors for putative hemopoiesis-related growth factors (c-fes, c-abl). Our data provide a basis for in-depth analysis of protooncogene expression in normal and neoplastic hemopoiesis.
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1989,
Haematology and blood transfusion,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1989,
Anticancer research,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
November 1984,
Cancer research,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
June 1990,
Zhonghua bing li xue za zhi = Chinese journal of pathology,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1988,
Cancer investigation,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1987,
Acta haematologica,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1984,
Blood,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1988,
International journal of cell cloning,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
January 1989,
Leukemia & lymphoma,
F Mavilio, and
N M Sposi, and
M Petrini, and
L Bottero, and
M Marinucci, and
G De Rossi, and
S Amadori, and
F Mandelli, and
C Peschle
April 1984,
Science (New York, N.Y.),
